AI Article Synopsis
- The study compares two surgical techniques for salvage radical prostatectomy: salvage Retzius-sparing robotic assisted radical prostatectomy (SRS-RARP) and salvage standard robotic assisted radical prostatectomy (SS-RARP), involving 72 patients across 9 centers.
- Results show that SRS-RARP leads to better urinary function outcomes, with more patients achieving continence, using fewer pads daily, and returning to continence sooner compared to SS-RARP.
- The findings suggest that SRS-RARP is a viable option for men with recurrent prostate cancer after unsuccessful primary treatments, and its benefits may encourage more frequent use of this technique.
Article Abstract
Purpose: Salvage radical prostatectomy is rare due to the risk of postoperative complications. We compare salvage Retzius-sparing robotic assisted radical prostatectomy (SRS-RARP) with salvage standard robotic assisted radical prostatectomy (SS-RARP).
Materials And Methods: A total of 72 patients across 9 centers were identified (40 SRS-RARP vs 32 SS-RARP). Demographics, perioperative data, and pathological and functional outcomes were compared using Student's t-test and ANOVA. Cox proportional hazard models and Kaplan-Meier curves were constructed to assess risk of incontinence and time to continence. Linear regression models were constructed to investigate postoperative pad use and console time.
Results: Median followup was 23 vs 36 months for SRS-RARP vs SS-RARP. Console time and estimated blood loss favored SRS-RARP. There were no differences in complication rates or oncologic outcomes. SRS-RARP had improved continence (78.4% vs 43.8%, p <0.001 for 0-1 pad, 54.1% vs 6.3%, p <0.001 for 0 pad), lower pads per day (0.57 vs 2.03, p <0.001), and earlier return to continence (median 47 vs 180 days, p=0.008). SRS-RARP was associated with decreased incontinence defined as >0-1 pad (HR 0.28, 95% CI 0.10-0.79, p=0.016), although not when defined as >0 pad (HR 0.56, 95% CI 0.31-1.01, p=0.053). On adjusted analysis SRS-RARP was associated with decreased pads per day. Lymph node dissection and primary treatment with stereotactic body radiation therapy were associated with longer console time.
Conclusions: SRS-RARP is a feasible salvage option with significantly improved urinary function outcomes. This may warrant increased utilization of SRS-RARP to manage men who fail nonsurgical primary treatment for prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JU.0000000000001939 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validity and reliability of the brief form of the normative male alexithymia scale among Chinese patients after radical prostatectomy.
Sci Rep
January 2025
Department of urinary surgery, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, 450003, Henan, China.
Alexithymia, a cognitive and emotional deficit characterized by difficulty in expressing emotions and identifying feelings, poses significant challenges in healthcare settings. Developing a reliable and valid tool to measure alexithymia in post-prostatectomy patients would not only aid healthcare professionals in identifying at-risk individuals but also facilitate early intervention and targeted support. This study aimed to translate the Brief Form of the Normative Male Alexithymia Scale (NMAS-BF) into Simplified Chinese, evaluate the reliability and validity of the Chinese version, and explore its influencing factors.
View Article and Find Full Text PDFPSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial.
World J Urol
January 2025
Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Propose: This study aimed to evaluate the efficacy and safety of neoadjuvant treatment of darolutamide, a next-generation androgen receptor inhibitor, plus androgen deprivation therapy (ADT) for patients with locally advanced prostate cancer (LAPC).
Methods: This single-arm, multicenter, open-label phase II trial (ClinicalTrials.gov: NCT05249712, 2022-01-01), recruited 30 localized high-risk/very high-risk prostate cancer (HRPCa/VHRPCa) patients from three centers in China between 2021 and 2023.
Quantitative 3-T Multiparametric MRI Parameters as Predictors of Aggressive Prostate Cancer.
Radiol Imaging Cancer
January 2025
From the Departments of Radiological Sciences (D.H.S.K., I.S., V.M., W.H., K.H.S., D.S.L., S.S.R.), Medicine Statistics Core (T.G.), Pathology (A.S.), and Urology (R.E.R., S.S.R.), David Geffen School of Medicine at UCLA, 885 Tiverton Dr, Los Angeles, CA 90095.
Purpose To determine which quantitative 3-T multiparametric MRI (mpMRI) parameters correlate with and help predict the presence of aggressive large cribriform pattern (LCP) and intraductal carcinoma (IDC) prostate cancer (PCa) at whole-mount histopathology (WMHP). Materials and Methods This retrospective study included 130 patients (mean age ± SD, 62.6 years ± 7.
View Article and Find Full Text PDFIntroduction: Radical cystectomy for patients who previously underwent both radical prostatectomy and prostatic bed radiation is technically challenging.
Case Presentation: A 78-year-old man with a history of radical prostatectomy and salvage radiation for prostate cancer was referred to our hospital for radical treatment of bladder cancer. After two cycles of neoadjuvant chemotherapy, he underwent robot-assisted radical cystectomy with real-time transrectal ultrasound guidance during dissection of the rectovesical space to minimize the risk of rectal injury.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!